WOMAC Hip Score in Children and Adolescents With Perthes Disease
NCT ID: NCT02795494
Last Updated: 2016-06-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
200 participants
OBSERVATIONAL
2007-05-31
2020-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The objective of this study is to determine the reliability and validity of the WOMAC hip scores in a pediatric population, between five and nineteen years of age, with Perthes disease. The results of this study will accomplish the above goal, thereby allowing either for widespread use of these measures in pediatric hip disorders or emphasizing the necessity for development of a pediatric hip specific outcome measure.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Multicenter Prospective Cohort Study on Current Treatments of Legg-Calvé-Perthes Disease
NCT02040714
Adolescent Projections During Transition in Prader-Willi Syndrome
NCT06279052
Global Hip Dysplasia Registry
NCT04117685
Evaluation of Aid to Diagnosis for Congenital Dysplasia of the Hip in General Practice
NCT04101903
The COllaborative Neonatal Network for the First CPAM Trial
NCT05701514
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
2. Hypothesis There is no true global hypothesis for the study since it is a validation/reliability study. There are hypotheses for each type of validity being studied.
For construct validity (using convergence), the hypothesis would be a priori hypothesis in this study related to convergent validity is that, assuming the WOMAC has construct validity in this population, then the hip specific outcome scores should be different for each Stulberg classification stage.
For construct validity (using extreme groups), the hypothesis would be a priori hypothesis in this study is that, assuming the measures have adequate construct validity in this population, the group of subjects being followed for treatment of an upper extremity fracture should have significantly better function, as indicated by a low score on the WOMAC and , compared to those with Perthes disease, who should have higher scores indicating poorer function.
For criterion validity, the hypothesis would be a priori hypothesis related to criterion validity in this study predicts that, assuming adequate concurrent validity of these measures in this population, there should be a negative correlation between the Activities Scale for Kids - Performance (ASK-p, an activity level outcome score) and the WOMAC. The reason for a negative correlation is that high scores on the generic measure indicate better function, whereas low scores on the hip specific measures indicate better function.
3. Research Method All subjects enrolled in the study will be given the initial set of questionnaires at the time of recruitment and asked to complete them at home, following the clinical follow-up visit, and return the questionnaires by mail using a self-addressed, stamped envelope which will be provided. All subjects will complete the WOMAC. Those with healed Perthes disease will also complete the ASK-p at the first visit to the clinic following consent into the study. Those in the comparison group with an upper extremity fracture will not complete the generic measure. This will comprise the initial time point of the study. Those subjects who do not complete all required questionnaires, at this time point, will be excluded from the study. Radiographs of the affected hip and pelvis will be obtained for each patient with healed Perthes disease at the time of the clinic visit, which would be obtained regardless of inclusion in the study in the course of standard clinical follow-up.
Those subjects with Perthes disease will also complete the WOMAC and measure two weeks following the initial time point. The questionnaires will be mailed to the subjects and they will be asked to complete the questionnaires and return them in a self-addressed, stamped envelope which will be provided. This will comprise the follow-up time point of the study. A reminder notification will be mailed at four weeks and a telephone call reminder at six weeks following the initial time point if the second series of questionnaires has not been returned. Those who do not complete the second series of questionnaires will be excluded from the reliability component of the study but maintained in the validity phase, provided the initial questionnaires were completed. Those with an upper-extremity fracture will not complete any additional questionnaires following the initial time point. The Stulberg classification will be determined, as outlined, following the initial time point but prior to analysis of the data.
4. Statistical Analysis All statistical analysis will be performed by a blinded, independent analyst. All analyses, with the exception of the weighted kappa statistic which will be calculated manually, will be performed with the use of S-PLUS software (version 6.2, Lucent Technologies, Inc.). The distribution of all questionnaire data will be determined with the use of frequency histograms to allow for the use of appropriate statistical tests. All statistical tests will be performed with α=0.05. The reported values will be the mean and the corresponding 95% confidence interval. Where two groups are compared, the mean difference between the groups and the 95% confidence interval of the difference will be reported.
There have been no previous studies or data of the WOMAC in a pediatric population. Using values obtained in studies of adults may not provide a good estimate for a power analysis in this population since other outcome measures, which have been validated in adults, have been shown to lack validity in children and adolescents. However, in order to estimate the sample size required for the correlation between the ASK-p and the hip outcome measures the previously reported adult derived values were required. On the basis of a minimum correlation of 0.6, which would be considered adequate, with α=0.05 and 80 per cent power, a total of 40 children are required for the study. Since there is no available evidence with which to estimate the correlation between these outcome measures, a liberal sample size will be recruited. In a similar study, except that generic as opposed to joint specific, outcome measures were used, a sample size of 196 subjects was recruited. Young et al recruited 200 subjects for their study in which several psychometric properties of the ASK-p were determined. A total of 200 subjects will be recruited across all centers participating in this study. There will be 100 subjects with an upper extremity fracture and 100 with healed Perthes disease. This sample size was chosen, in part, on the basis of the maximum number of subjects with healed Perthes which would be feasible to recruit over the time horizon of the study, which will be six months. It is anticipated that a minimum of four centers will participate in the study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Perthes Group
Participants with Perthes disease. Will be given WOMAC questionnaire at baseline and WOMAC questionnaire at 2 weeks, and ASK-P questionnaire at baseline.
WOMAC questionnaire at baseline
Patient-reported pain, stiffness and physical function outcome score
ASK-P questionnaire at baseline
Patient-reported activity level score
WOMAC questionnaire at 2 weeks
Patient-reported pain, stiffness and physical function outcome score
Fracture Control Group
Participants with an upper extremity fracture but no hip-related conditions. Will be given WOMAC questionnaire at baseline.
WOMAC questionnaire at baseline
Patient-reported pain, stiffness and physical function outcome score
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
WOMAC questionnaire at baseline
Patient-reported pain, stiffness and physical function outcome score
ASK-P questionnaire at baseline
Patient-reported activity level score
WOMAC questionnaire at 2 weeks
Patient-reported pain, stiffness and physical function outcome score
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Healed Perthes disease. Healed Perthes disease will be defined radiographically, in the accepted fashion, by the appearance of normal bone density of the femoral head. The restriction of those with Perthes disease to only those with resolution of the disease will prevent heterogeneity of the clinical presentation and anticipated functional abilities which would occur by including those in the acute phases of the disease, thereby reducing potential bias.
* All participants will have to be able to complete the questionnaires in English and, for those with Perthes disease, be able to complete the questionnaires again two weeks following the initial completion.
Exclusion Criteria
* Those with Perthes disease who demonstrate acute phases of the disease will be excluded. Acute phases of the disease will be defined in the accepted fashion, by the radiographic presence of fragmentation or reossification of the femoral head.
* Those who do not provide consent for participation in the study will be excluded, as will those who either cannot complete the questionnaire in English or are unable to complete a second set of questionnaires at two weeks.
* Those with cognitive impairment, precluding completion of the questionnaires, will be excluded.
* All those with concomitant medical problems will be excluded due to possible confounding of the clinical outcome measures.
5 Years
19 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
British Columbia Children's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kishore Mulpuri
Pediatric Orthopaedic Surgeon
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kishore Mulpuri, MBBS, MS(Ortho), MHSc
Role: PRINCIPAL_INVESTIGATOR
Provincial Health Services Authority
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
British Columbia Children's Hospital
Vancouver, British Columbia, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Young NL, Williams JI, Yoshida KK, Wright JG. Measurement properties of the activities scale for kids. J Clin Epidemiol. 2000 Feb;53(2):125-37. doi: 10.1016/s0895-4356(99)00113-4.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H0700752
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.